The RIGHT Fund has announced 10 new R&D projects for 2021. One of them is the “Repeat Dose Toxicity Studies to Confirm the Safety of Novel TTCA Antitubercular Agent” project* conducted by the Medicinal Chemistry Team at Institut Pasteur Korea (IPK). The Medicinal Chemistry Team is using animal models to study the in vivo toxicity of anti-tuberculosis drug candidate, TTCA, identified through IPK’s image-based screening.

* See the details of IPK’s project selected for the 2021 RIGHT Fund Technical Accelerator Award (Click)

 + + + + +

Financial News (2021.7.27)

RIGHT Fund provides additional support of 13.6 billion KRW for new infectious disease R&D

Go to the Article >>